Working… Menu

Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00003646
Recruitment Status : Completed
First Posted : May 3, 2004
Last Update Posted : July 7, 2011
Information provided by:

Brief Summary:

RATIONALE: Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells.

PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating patients who have stage III or stage IV melanoma that has not responded to previous treatment.

Condition or disease Intervention/treatment Phase
Stage IV Melanoma Stage III Melanoma Recurrent Melanoma Drug: allovectin-7 Phase 2

Detailed Description:

OBJECTIVES: I. Demonstrate an objective clinical response (partial or complete) with a median duration of at least 4 months in 15% of patients with stage III or IV melanoma treated with Allovectin-7. Allovectin-7 is a direct gene transfer immunotherapeutic agent.

II. Determine the benefits, risks, and side effects of Allovectin-7 in this patient population.

PROTOCOL OUTLINE: This is a multicenter study. Patients receive an intratumoral injection of Allovectin-7 once weekly for 6 weeks. At week 9, a complete disease status assessment is performed. Patients with stable or responding disease may receive additional courses of 6 injections.


A total of 70 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 78 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Allovectin-7 as an Immunotherapeutic Agent in Patients With Stages III and IV Melanoma
Study Start Date : August 1998
Actual Primary Completion Date : March 2002
Actual Study Completion Date : May 2002

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers:   No


--Disease Characteristics--

  • Histologically confirmed melanoma; Stage III with locoregional disease, in transit metastasis, or nodal disease OR Stage IV metastatic disease in skin, subcutaneous tissue, lymph node(s), and/or lung
  • At least 1 metastasis for which surgery is not deemed to be a curative option
  • Relapsed from or has not responded to frontline chemotherapy or biotherapy
  • At least 1 measurable tumor at least 1 cm by 1 cm, but less than 5 cm by 5 cm
  • No history of brain metastases or visceral metastases other than lung metastases

--Prior/Concurrent Therapy--

  • Biologic therapy: See Disease Characteristics; At least 4 weeks since prior biologic therapy
  • Chemotherapy: See Disease Characteristics; At least 4 weeks since prior chemotherapy
  • Endocrine therapy: No concurrent immunosuppressive drugs
  • Radiotherapy: At least 4 weeks since prior radiotherapy
  • Surgery: At least 2 weeks since prior major surgery
  • Other: No other concurrent anticancer drug therapy, or any other experimental therapy

--Patient Characteristics--

  • Age: 18 and over
  • Performance status: Karnofsky 80-100%
  • Life expectancy: At least 6 months
  • Hematopoietic: WBC at least 3,000/mm3; Platelet count at least 100,000/mm3; Hemoglobin at least 9 g/dL
  • Hepatic: Bilirubin no greater than 2.0 mg/dL; SGOT/SGPT less than 3 times upper limit of normal; PT/PTT normal LDH and albumin normal
  • Renal: Creatinine no greater than 2.0 mg/dL
  • Cardiovascular: No uncontrolled hypertension; No New York Heart Association class III or IV disease
  • Other: HIV negative; Negative pregnancy test; Fertile patients must use effective contraception; No active autoimmune disease; No active infection requiring parenteral antibiotics; No uncontrolled diabetes mellitus; No other prior malignancy in the past 5 years except skin cancer or stage 0-II cervical cancer; No significant psychiatric disorders

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00003646

Layout table for location information
United States, Minnesota
Mayo Clinic Cancer Center
Rochester, Minnesota, United States, 55905
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263-0001
United States, Texas
Physician Reliance Network, Inc.
Dallas, Texas, United States, 75246
Sponsors and Collaborators
Layout table for investigator information
Study Chair: Jennifer Fernandez Vical
Layout table for additonal information
Responsible Party: Dmitri D. Kharkevitch, MD, PhD, Vical Incorporated Identifier: NCT00003646    
Obsolete Identifiers: NCT00416806
Other Study ID Numbers: CDR0000066735
VCL-1005-205 ( Other Identifier: Vical )
First Posted: May 3, 2004    Key Record Dates
Last Update Posted: July 7, 2011
Last Verified: July 2011
Keywords provided by Vical:
adult solid tumor
body system/site cancer
recurrent melanoma
skin tumor
solid tumor
stage III melanoma
stage IV melanoma
stage, melanoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas